

17.06.2022

<b>08:25 - 08:30</b>	<b>Welcome to the ESMO Gynaecological Cancers Congress 2022</b>	<b>Auditorium 1A</b>
	Moderation: S. Banerjee <sup>1</sup> , D. Lorusso <sup>2</sup> , <sup>1</sup> Gynaecology Department, The Royal Marsden Hospital - Chelsea, London, GB, <sup>2</sup> Gynecologic Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
<b>08:30 - 10:00</b>	<b>Management of endometrial cancer in the molecular era</b>	<b>Auditorium 1A</b>
	Moderation: C. Creutzberg, Radiation Oncology Dept, LUMC - Universitair Medisch Centrum, Leiden, NL	
08:30 - 08:55	<b>Recent developments in surgery for early-stage disease</b>	
	<u>C. Marth</u> , Innsbruck Medical University, Innsbruck, AT	
08:55 - 09:20	<b>Recent developments in adjuvant treatment</b>	
	<u>C. Creutzberg</u> , LUMC - Universitair Medisch Centrum, Leiden, NL	
09:20 - 09:45	<b>New treatment options for advanced and metastatic disease</b>	
	<u>A. Leary</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
09:45 - 10:00	<b>Live Q&amp;A</b>	
<b>10:00 - 10:30</b>	<b>Coffee break</b>	<b>Exhibition area</b>
<b>10:30 - 12:00</b>	<b>Biomarkers in clinical practice and future perspective for gynaecological cancers</b>	<b>Auditorium 1A</b>
	Moderation: V. Makker, Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York City, US	
10:30 - 10:50	<b>Should we really use PD-L1 as a selection driver in cervical cancer?</b>	
	<u>B. Monk</u> , Arizona Oncology (US Oncology Network), Phoenix, US	
10:50 - 11:10	<b>MMR status, TMB or both: How to identify endometrial cancer patients who benefit the most from immunotherapy</b>	
	<u>V. Makker</u> , Memorial Sloan-Kettering Cancer Center, New York City, US	
11:10 - 11:30	<b>Digging into molecular characterization of high-grade ovarian cancer: BRCA, HRD and beyond</b>	
	<u>N. Concin</u> , Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, AT	
11:30 - 11:50	<b>The role of MAPK pathway to select therapy in low-grade ovarian cancer</b>	
	<u>S. Banerjee</u> , The Royal Marsden Hospital - Chelsea, London, GB	
11:50 - 12:00	<b>Live Q&amp;A</b>	

<b>12:15 - 13:00</b>	<b>Poster display session</b>	<b>Exhibition area</b>
<b>13:00 - 14:00</b>	<b>GSK - Industry satellite symposium</b>	<b>Auditorium 1A</b>
<b>14:15 - 14:45</b>	<b>Keynote lecture: Practice-change and progress in the treatment of gynaecological cancers</b>	<b>Auditorium 1A</b>
	Moderation: D. Lorusso, Gynecologic Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
14:15 - 14:20	<b>Introduction</b>	
	<u>D. Lorusso</u> , Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
14:20 - 14:40	<b>Practice-change and progress in the treatment of gynaecological cancers</b>	
	<u>E. Pujade-Lauraine</u> , ARCAGY-GINECO, Paris, FR	
<b>14:50 - 15:50</b>	<b>Shall all patients regardless of biomarker status receive immunotherapy in cervical cancer?</b>	<b>Auditorium 1A</b>
	Moderation: M.R. Mirza <sup>1</sup> , D. Lorusso <sup>2</sup> , <sup>1</sup> Department Of Oncology, Rigshospitalet, Copenhagen, DK, <sup>2</sup> Gynecologic Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
14:50 - 15:00	<b>Introduction and first vote</b>	
	<u>M.R. Mirza</u> , Rigshospitalet, Copenhagen, DK	
15:00 - 15:20	<b>Pro</b>	
	<u>N. Colombo</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
15:20 - 15:40	<b>Con</b>	
	<u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, ES	
15:40 - 15:50	<b>Second vote and conclusions</b>	
	<u>D. Lorusso</u> , Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
<b>15:50 - 16:15</b>	<b>Coffee break</b>	<b>Exhibition area</b>

<b>16:15 - 17:45</b>	<b>Ovarian cancer management in the PARP inhibitor era</b> Moderation: S. Banerjee, Gynaecology Department, The Royal Marsden Hospital - Chelsea, London, GB	<b>Auditorium 1A</b>
16:15 - 16:40	<b>The role of surgery in newly-diagnosed and recurrent ovarian cancer in the era of targeted therapies</b> <u>S. Mahner</u> , LMU - Ludwig Maximilians University - Grosshadern, Munich, DE	
16:40 - 17:05	<b>How to make the best of PARP inhibitor therapy: When, who and how?</b> <u>R. Coleman</u> , US Oncology Research, The Woodlands, US	
17:05 - 17:30	<b>How to treat ovarian cancer post and beyond PARP inhibitors?</b> <u>S. Lheureux</u> , University Health Network - Princess Margaret Cancer Center, Toronto, CA	
17:30 - 17:45	<b>Live Q&amp;A</b>	
<b>18:00 - 19:00</b>	<b>Industry satellite symposium 2</b>	<b>Auditorium 1A</b>

18.06.2022

<b>08:30 - 10:00</b>	<b>The evolving landscape in cervical cancer treatment</b>	<b>Auditorium 1A</b>
	Moderation: D. Lorusso <sup>1</sup> , A. Oaknin <sup>2</sup> , <sup>1</sup> Gynecologic Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, <sup>2</sup> Medical Oncology Dept., Vall d'Hebron University Hospital, Barcelona, ES	
08:30 - 08:55	<b>Surgical approach in early-stage cervical cancer: Keeping the principles and reducing morbidity</b>	
	<u>P. Ramirez</u> , The University of Texas MD Anderson Cancer Center - Main Building, Houston, US	
08:55 - 09:20	<b>Is immunotherapy ready for prime time in cervical cancer?</b>	
	<u>D. Lorusso</u> , Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
09:20 - 09:45	<b>The role of ADC and other targeted therapies in the treatment or recurrent/metastatic cervical cancer</b>	
	<u>S. Pignata</u> , Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT	
09:45 - 10:00	<b>Live Q&amp;A</b>	
<b>10:00 - 10:30</b>	<b>Coffee break</b>	<b>Exhibition area</b>
<b>10:30 - 12:00</b>	<b>Clinical trials highlights</b>	<b>Auditorium 1A</b>
<b>12:00 - 13:00</b>	<b>Lunch and Poster viewing</b>	<b>Exhibition area</b>
<b>13:00 - 14:00</b>	<b>Industry satellite symposium 3</b>	<b>Auditorium 1A</b>

<b>14:15 - 15:45</b>	<b>Managing the consequences of cancer treatments</b>	<b>Auditorium 1A</b>
	Moderation: S. Banerjee, Gynaecology Department, The Royal Marsden Hospital - Chelsea, London, GB	
14:15 - 14:35	<b>Fertility-preservation option in gynaecological cancer</b>	
	<u>F. Amant</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
14:35 - 14:55	<b>How to optimise older patients for cancer treatments?</b>	
	<u>C. Falandry</u> , Lyon Sud Hospital Center, Pierre Benite, FR	
14:55 - 15:15	<b>Management of immunotherapy and targeted therapies-induced toxicities</b>	
	<u>A.J. Gonzalez Martin</u> , Clinica Universidad de Navarra, Madrid, ES	
15:15 - 15:35	<b>Radiotherapy-related toxicities in gynaecological cancers</b>	
	<u>A. Taylor</u> , Royal Marsden Hospital NHS Foundation Trust, London, GB	
15:35 - 15:45	<b>Live Q&amp;A</b>	
<b>15:45 - 16:10</b>	<b>Coffee break</b>	<b>Exhibition area</b>
<b>16:10 - 17:40</b>	<b>Rare gynaecological cancers</b>	<b>Auditorium 1A</b>
	Moderation: I. Ray-Coquard, Medical Oncology Department, Centre Léon Bérard, Lyon, FR	
16:10 - 16:35	<b>Histo-molecular classification of rare tumours, predictive markers and druggable targets</b>	
	<u>I. Mcneish</u> , Imperial College London - Hammersmith Hospital, London, GB	
16:35 - 17:00	<b>Current management and ongoing clinical trials</b>	
	<u>D.S. Tan</u> , NUHS - National University Health System, Singapore, SG	
17:00 - 17:25	<b>Future clinical research and unmet needs</b>	
	<u>I. Ray-Coquard</u> , Centre Léon Bérard, Lyon, FR	
17:25 - 17:40	<b>Discussion</b>	
<b>17:40 - 17:45</b>	<b>Closing remarks</b>	<b>Auditorium 1A</b>
	Moderation: S. Banerjee <sup>1</sup> , D. Lorusso <sup>2</sup> , <sup>1</sup> Gynaecology Department, The Royal Marsden Hospital - Chelsea, London, GB, <sup>2</sup> Gynecologic Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	